1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) is sponsored by National Institute of Mental Health (NIMH) / NIH. This Notice of Funding Opportunity (NOFO) encourages applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause).
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Mood and Psychosis Symptoms during the Menopause Transition (R01, R21 Clinical Trial Optional) | Research Funding National Institutes of Health Mood and Psychosis Symptoms during the Menopause Transition (R01, R21 Clinical Trial Optional) The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause).
In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption, emotion dysregulation, and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts This NOFO uses the R01 grant mechanism, while the companion NOFO PAR-25-282 uses the R21 mechanism.
Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.
R01 Due Dates: Feb 5, Jun 5, Oct 5 R21 Due Dates: Feb 16, Jun 16, Oct 16 PAR-25-281 Expiration Date January 08, 2028 This NOFO encourages applications that incorporate teams with varied scientific backgrounds.
Teams may include but are not limited to members from the fields of neuroscience, engineering, endocrinology, epidemiology, reproductive medicine, gerontology, gynecology, pharmacology, psychiatry, and psychology with the expertise necessary to conduct rigorous research. Teams led by or including those with lived experience with perimenopausal depression or psychosis are highly encouraged.
Engineering and Physical Sciences Medical - Clinical Science
According to the current listing, eligibility includes: Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, small businesses, and foreign organizations. Specific details are available in Section III. Confirm the full requirements in the official notice before applying.
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) is funded by National Institute of Mental Health (NIMH) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Notice of Special Interest (NOSI): SBIR/STTR High-Priority Areas for Digital Mental Health Innovations is sponsored by National Institute of Mental Health (NIMH) / NIH. This NOSI encourages Small Business Concerns (SBCs) to submit SBIR and STTR grant applications for developing, refining, and evaluating digital mental health technologies. This includes mobile health (mHealth) and health information technology.
Notice of Special Interest (NOSI): SBIR/STTR High-Priority Areas for Digital Mental Health Innovations (NOT-MH-24-120) is sponsored by National Institute of Mental Health (NIMH) / NIH. This NOSI encourages Small Business Concerns (SBCs) to submit SBIR and STTR grant applications that propose to develop, refine, and evaluate digital mental health technologies.
The Health and Extreme Weather highlighted topic went live September 1, 2026 with eleven awarding institutes and expires May 1, 2028. There is no set-aside, no separate deadline, and no review criteria — which makes the institute-by-institute language the only real signal, and it is not uniform.
Read articleThe NOURISH Autoimmunity Digital Health Challenge runs three phases to August 2028: 10 winners at $20,000, then 5 at $30,000, then 3 at $100,000. It is a prize competition, not a grant — no indirect costs, no cost reimbursement, and a rule that quietly disqualifies the obvious applicant.
Read articlePMHCA (HRSA-26-058) makes $9.79 million available for up to 22 awards of up to $445,000 to build tele-consultation networks that help pediatric primary care providers manage children's behavioral health. The catch buried in the eligibility section: applicants must NOT already hold a PMHCA award — which effectively reserves the new-state lane for the eight unfunded states and territories, plus tribes everywhere. Here's how to read it and what wins.
Read article